help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brue, T.
Right arrow Articles by Jaquet, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brue, T.
Right arrow Articles by Jaquet, P.

Journal of Clinical Endocrinology & Metabolism, Vol 74, 577-584, Copyright © 1992 by Endocrine Society

ARTICLES

Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine

T Brue, I Pellegrini, G Gunz, I Morange, D Dewailly, J Brownell, A Enjalbert and P Jaquet
Service d'Endocrinologie, Hopital Nord, Marseille, France.

In 21 patients with prolactinomas resistant to bromocriptine, we studied the effects of CV 205-502 on PRL hypersecretion and tumor mass, as assessed by consecutive computed tomography examinations. Cell culture studies were performed in 9 of such tumors. In 11 patients (group I; 52%) with a mean baseline plasma PRL level of 468 +/- 160 micrograms/L (+/- SE), normal PRL values were achieved after 1-6 months of treatment with 0.1-0.5 mg/day CV 205-502. Tumor size was reduced by 25% or more in 6 of 11 patients. In group II (n = 10), PRL levels (948 +/- 538 micrograms/L at baseline) were reduced by 48% after treatment with 0.1 mg/day CV 205-502. A progressive increase in the daily dose up to 0.5 mg did not further improve the partial reduction of PRL. No reduction in tumor size was observed in this group. The cell culture studies showed that 1) a brief exposure to both drugs provoked PRL suppression lasting 3 days; 2) in group I, CV 205-502 suppressed PRL release more efficiently than bromocriptine, with a maximal inhibition of 72% at 10(-9) mol/L; and 3) in group II, CV 205-502 only achieved a 26% inhibition of PRL release at 10(-8) mol/L, superimposable to that of bromocriptine. These data indicate that in at least half of such adenomas resistant to bromocriptine, CV 205-502, probably due to its higher affinity toward the D2 dopamine receptor, can overcome such resistance.


This article has been cited by other articles:


Home page
 Endocr. Rev.Home page
M. P. Gillam, M. E. Molitch, G. Lombardi, and A. Colao
Advances in the Treatment of Prolactinomas
Endocr. Rev., August 1, 2006; 27(5): 485 - 534.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
A. Barlier and P. Jaquet
Quinagolide - a valuable treatment option for hyperprolactinaemia
Eur. J. Endocrinol., February 1, 2006; 154(2): 187 - 195.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Di Sarno, M. L. Landi, P. Cappabianca, F. Di Salle, F. W. Rossi, R. Pivonello, C. Di Somma, A. Faggiano, G. Lombardi, and A. Colao
Resistance to Cabergoline as Compared with Bromocriptine in Hyperprolactinemia: Prevalence, Clinical Definition, and Therapeutic Strategy
J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5256 - 5261.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Colao, A. Di Sarno, M. L. Landi, F. Scavuzzo, P. Cappabianca, R. Pivonello, R. Volpe, F. Di Salle, S. Cirillo, L. Annunziato, et al.
Macroprolactinoma Shrinkage during Cabergoline Treatment Is Greater in Naive Patients Than in Patients Pretreated with Other Dopamine Agonists: A Prospective Study in 110 Patients
J. Clin. Endocrinol. Metab., June 1, 2000; 85(6): 2247 - 2252.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
P. Jaquet, L. Ouafik, A. Saveanu, G. Gunz, F. Fina, H. Dufour, M. D. Culler, J. P. Moreau, and A. Enjalbert
Quantitative and Functional Expression of Somatostatin Receptor Subtypes in Human Prolactinomas
J. Clin. Endocrinol. Metab., September 1, 1999; 84(9): 3268 - 3276.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. Ferone, S. Lastoria, A. Colao, P. Varrella, G. Cerbone, W. Acampa, B. Merola, M. Salvatore, and G. Lombardi
Correlation of Scintigraphic Results Using 123I-Methoxybenzamide with Hormone Levels and Tumor Size Response to Quinagolide in Patients with Pituitary Adenomas
J. Clin. Endocrinol. Metab., January 1, 1998; 83(1): 248 - 252.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Colao and G. Lombardi
Immunocytochemical localization of gonadotropin and gonadal steroid receptors in human pineal glands.
J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2756 - 2757.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Colao, A. Di Sarno, F. Sarnacchiaro, D. Ferone, G. Di Renzo, B. Merola, L. Annunziato, and G. Lombardi
Prolactinomas Resistant to Standard Dopamine Agonists Respond to Chronic Cabergoline Treatment
J. Clin. Endocrinol. Metab., March 1, 1997; 82(3): 876 - 883.
[Abstract] [Full Text] [PDF]

Home page
 DTBHome page
New drugs for hyperprolactinaemia
DTB, September 1, 1995; 33(9): 65 - 67.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1992 by The Endocrine Society